Thought Leadership

Latest Report


Biopharma and Medtech Half-Year Review 2021

Despite the continuing pandemic, the biopharma sector saw a return to relative stability during the first half of 2021. Remote operations are proving effective, deals are being made, and clinical research has resumed in many areas. Compared to the same period in 2020, the medtech industry has witnessed a reversal of fortunes. Those producing…

Report library


Evaluate Vantage 2021 Preview

Biopharma’s role in trying to bring the COVID-19 pandemic to an end has made household names of companies large and small, and cutting-edge technologies like mRNA…


Evaluate Vantage COVID-19 Report

Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…


Evaluate Pharma Orphan Drug Report 2020

What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…